Novartis AG Registered Shares
NOVN: XSWX (CHE)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
CHF 63.00 | Dqfg | Wtwqksj |
Novartis Reports Steady Fourth Quarter With New and Core Drugs Offsetting Generic Pressures
Novartis reported fourth-quarter results and provided 2023 guidance largely in line with our expectations, and we don’t expect any major changes to our fair value estimate. With the stock trading close to our fair value, we believe the market is appropriately assessing Novartis’ outlook. Solid recent drug launches and pipeline opportunities look well positioned to offset patent losses, which reinforces our wide moat rating.